Agomelatine treatment is generally relevant for patients experiencing Major Depressive Episodes in adulthood, focusing on relief across several distinct symptomatic domains. Its therapeutic use focuses on Major Depressive Disorder, a condition marked by mood disturbances and symptoms like deep sadness, loss of interest in activities, and sleep disturbances. It is commonly used when symptoms are moderate-to-severe or during the long-term maintenance phase to prevent relapse.

The medicine is applied in addressing core symptoms of a clinical mood disorder, including persistent low mood, emotional pain, and overwhelming distress, as well as associated sleep problems and reduced motivation. The medication is applied across therapeutic domains where additional symptomatic support is needed.

Supporting Sleep and Restful Periods

This domain covers the common depressive symptom of sleep problems, which includes difficulty initiating sleep and poor quality rest. The therapeutic benefit is supportive management of associated sleep problems, which contributes to improved comfort and supports general well-being during symptomatic phases.

Quick Fact: Relief for Sleep Disturbances This medicine may assist in seeking more consistent, quality rest during phases when symptoms become more noticeable.

Regulatory References

1. European Medicines Agency

Agomelatine is designated for use in adults generally aged 18 to under 75 years. Official eligibility rules strictly define several populations for whom the medicine is prohibited or not recommended.

Absolute Contraindications

The medicine is contraindicated in patients with active liver disease, cirrhosis, or any form of hepatic impairment. This non-eligibility rule applies if baseline liver enzymes (transaminases) exceed three times the Upper Limit of Normal (> 3 imes ULN). Additionally, co-administration with potent CYP1A2 inhibitors, such as fluvoxamine or ciprofloxacin, is an absolute contraindication.

Age-Related Eligibility Rules

Use is formally not recommended for the pediatric population (under 18 years) as safety and efficacy have not been established. For older adults aged 75 years and above at treatment initiation, use is also not recommended due to lack of documented efficacy.

Other Eligibility Limitations

Official labeling states that use is not recommended in elderly patients with dementia. The medicine requires caution in patients with severe renal impairment due to limited clinical data. For both pregnancy and lactation, use is officially not recommended.

Connection to the Overall Eligibility Profile

Regulatory documents establish that only the adult population under 75 years of age is the approved cohort for Agomelatine use. Eligibility is determined by absolute exclusions based on physiological status, particularly liver function, and by formal restrictions concerning age and reproductive status.

Agomelatine is metabolized primarily by the liver enzyme Cytochrome P450 1A2 (CYP1A2), with minor involvement from CYP2C9 and CYP2C19. This metabolic pathway is central to the drug's official interaction profile, which is structured around substances that modify these enzyme activities.

Contraindicated Combinations

Co-administration with potent CYP1A2 inhibitors is contraindicated. Specific examples of medicines that fall into this classification include the antidepressant fluvoxamine and the antibiotic ciprofloxacin. The concurrent use of these potent inhibitors markedly increases agomelatine exposure, sometimes over 60-fold, necessitating this restriction.

Interactions Requiring Caution

Caution is advised when agomelatine is used concomitantly with moderate CYP1A2 inhibitors, such as propranolol or oestrogens. These agents can also increase agomelatine exposure several-fold. Concomitant use with medicinal products associated with the risk of hepatic injury also requires careful consideration.

Other Interactions

Substances that induce CYP1A2, such as smoking (especially heavy smoking, ge 15 cigarettes/day) or the antibiotic rifampicin, are documented to decrease the bioavailability of agomelatine. Agomelatine does not induce or inhibit CYP450 enzymes and is not expected to modify the exposure of co-administered medicines metabolized by these enzymes. The combination of agomelatine and alcohol is not advisable.

Dual Receptor Targeting and Neurotransmitter Enhancement

Agomelatine initiates its action through a precise, dual-target mechanism in the brain: it acts as an agonist (activator) at the MT1 and MT2 melatonin receptors, while simultaneously acting as a selective antagonist (blocker) at the 5- HT2 C serotonin receptors. This blockade removes an inhibitory control, leading to the disinhibition and enhanced functional availability of both norepinephrine and dopamine in the frontal cortex, modulating neurochemical signaling within circuits that regulate central nervous system activity.

---

Restoring Biological Timing (Chronobiotic Effect)

The activation of MT1 and MT2 receptors provides a strong signal to the brain's master clock, the Suprachiasmatic Nucleus (SCN). This signal's function is purely chronobiotic, meaning it helps resynchronize or stabilize the timing of the body’s internal biological rhythms, which are often dysregulated. This core mechanistic domain contributes to the phase adjustment of the sleep-wake cycle and modulation of physiological phase relationship between internal processes.

How to Use Agomelatine — Administration Guidelines

This section outlines the administration instructions for Agomelatine.

Administration and Dosage

Guideline	Instruction
Route	Oral (by mouth).
Dose	The starting dose is 25 mg once daily.
Titration	The dose may be increased to a maximum of 50 mg once daily if the response is inadequate after two weeks, following professional guidance.
Timing	The dose must be taken once daily at bedtime.
Preparation	The tablet must be swallowed whole, with or without food.
Missed Dose	If a dose is missed, take the next dose at the usual time the following night. Do not take a double dose to make up for the missed one.

---

Procedural and Population Requirements

Special Conditions:

• Treatment Duration: The medicine should be continued for several months (typically 6 months or more) after symptoms have gone away (remission).
• Monitoring: Liver function must be checked using blood tests (transaminases) before starting treatment and periodically throughout the course (e.g., at 3 weeks, 6 weeks, 12 weeks, and 24 weeks), and whenever the dose is increased.

Age and Health Specifics:

• Elderly Patients (65-75 years): Use with caution; any increase to 50 mg requires careful monitoring.
• Patients Over 75 years: Use is generally not recommended.
• Hepatic Impairment: The use of this medicine is contraindicated (must not be used) in patients with liver problems.

Evidence for Use in Acute Major Depressive Episodes (MDD)

The core clinical evaluation for agomelatine was primarily conducted through short-term, randomized controlled trials (RCTs) in adult populations. These studies, typically lasting 6 to 12 weeks, monitored symptom intensity using standardized scales. Trials compared the medicine against an inactive placebo and other established treatments, with systematic reviews integrating available data to characterize the observed patterns of symptom evolution.

---

Evidence for Addressing Associated Sleep Disturbances

Research monitored sleep patterns related to the administration of Agomelatine, which are outcomes related to systemic imbalance often experienced during periods of heightened symptom activity. Studies used both patient-reported outcomes for assessing sleep quality and objective measurements of sleep architecture. Patient reports often described positive patterns, but findings regarding objective total sleep time were noted to vary across reviews when compared to placebo.

---

Evidence for Use in Maintenance and Relapse Prevention

Longer-term research explored the maintenance phase using randomized discontinuation trials. These studies monitored the time until the recurrence of a Major Depressive Episode in patients whose condition had stabilized. Research described the recurrence rates observed in the group continuing treatment compared to the placebo group over intermediate follow-up durations, typically up to 6 months.

---

Evidence in Special Subgroups and Limitations

Limited research examined the administration of the medicine in specific contexts like Generalized Anxiety Disorder (GAD) or in patients with certain co-existing conditions. Research also explored use in older adults (aged 65 years and above), and the observed patterns contribute to the information base for this subgroup. However, key limitations exist: follow-up durations for many core trials were short, evidence quality varies across studies, and data for long-term effects and other special groups remain insufficient.

Common questions about Агомелатин (FAQ)

Q: What are the proper storage conditions for this medication?

Regulatory documents state that this medication should be stored at controlled room temperature, typically between 20 C to 25 C (68 F to 77 F). The product information indicates that the medication should be protected from moisture.

Q: What are the specific contraindications for taking this drug?

According to the official product information, this medication is contraindicated (should not be used) if a patient is currently taking a Monoamine Oxidase Inhibitor (MAOI) or has recently stopped MAOI treatment within the last 14 days. This is due to the potential for Serotonin Syndrome when these types of medications are combined.

Q: Does this medication make you sleepy or affect my ability to drive?

Official information indicates that this medication can cause drowsiness, sedation, and may impair judgment, thinking, and motor skills. Patients should be cautious when performing activities requiring mental alertness, such as driving or operating complex machinery, until they understand how the drug affects them.

Q: Is it safe to drink alcohol while taking this medicine?

Regulatory sources advise against the use of alcohol during therapy. This is because the medication can intensify the sedative effects of alcohol, potentially increasing the risk of drowsiness and impaired coordination.

Q: Is this medication safe to take during pregnancy?

Available data from case reports and studies in pregnant women have not identified a specific drug-associated risk of major birth defects or miscarriage. However, official information notes that newborns whose mothers took this type of medication during the third trimester may develop temporary signs like breathing difficulties and irritability after birth.

Q: Is it safe to take this medication long-term (e.g., more than 6 months)?

Official guidance notes that continued treatment may be required for several months after an initial positive response. For patients using the medication long-term, regulatory documents state that the patient must be periodically reassessed by a healthcare provider to determine the continued need for maintenance treatment.

Q: Can children 2 years old use it?

According to the official prescribing information, this medication is not approved for use in pediatric patients, which includes children under the age of 18. Use and safety in this age group have not been established by the regulatory agency.

How to Store and Dispose of Agomelatine

Official regulatory labeling dictates specific conditions for the storage and disposal of agomelatine tablets to maintain product stability and safety.

Storage Requirements

Condition	Requirement
Temperature	No special storage conditions are required.
Protection	Must be stored in the original package to protect from moisture.
Shelf Life	The stability period is 3 years for the product as packaged.
Child Safety	Must be kept out of the reach and sight of children.

The requirement of no special conditions means the tablets are stable at normal ambient room temperature. The original packaging, typically a sealed blister pack, must be preserved to prevent moisture damage.

Disposal Instructions

Official labeling states there are no special requirements for disposal of unused medicine or waste material. However, all unused or expired product must be discarded in accordance with local requirements, often involving returning it to a pharmacist or a designated drug collection program.